Skip to content

The Effect of Danzhu Fuyuan Granule as Adjunctive Therapy for Chronic Stable Angina, Vascular Dementia and Idiopathic Membranous Nephropathy: A Bayesian Basket Trial

The Effect of Danzhu Fuyuan Granule as Adjunctive Therapy for Chronic Stable Angina, Vascular Dementia and Idiopathic Membranous Nephropathy: A Bayesian Basket Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04498962
Enrollment
240
Registered
2020-08-05
Start date
2020-08-31
Completion date
2021-12-01
Last updated
2020-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Stable Angina, Idiopathic Membranous Nephropathy, Vascular Dementia

Keywords

Danzhu Fuyuan Granule; Basket Trial

Brief summary

This study is designed as a bayesian basket trial , which aims to evaluate the efficacy of Danzhu Fuyuan Granule in patients with Chronic Stable Angina, Vascular Dementia and Idiopathic Membranous Nephropathy

Interventions

DRUGDanzhu Fuyuan Granule

Danzhu Fuyuan Granules,2 times / day, 1 bag / time, one time in the morning and one time in the evening. It is recommended to add the same amount of boiling water as the particles to soak for 30 seconds, and then add 5 times boiling water to dissolve until completely dissolved.The treatment cycle of each arm: 8 weeks for Chronic Stable Angina, 6 months for Vascular Dementia and 6 months for Idiopathic Membranous Nephropathy.

Sponsors

Jingqing Hu
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

Eligibility Criteria for Chronic Stable Angina group Inclusion criteria for Chronic Stable Angina group 1. Patient must be between the ages of 40 and 70 years 2. Evidence of coronary artery disease that consists of a well-documented medical history (over 3 months prior to the enrollment) of myocardial infarction or significant coronary artery disease with noninvasive or angiographic confirmation. 3. Patient must match the diagnostic criteria for chronic stable angina set by Chinese Medical Association; 4. The number of angina pectoris attacked in the past 3 months was more than 2 times per week 5. Class I or Class II, Grading of Angina Pectoris by the Canadian Cardiovascular Society Classification System 6. Patients who met the clinical diagnostic criteria for Syndrome of intermingled phlegm and blood stasis with chronic stable angina; 7. The results of Treadmill Exercise Test were positive; 8. All other Traditional Chinese Medicine interventions (including decoction, granule, proprietary Chinese medicine, acupuncture, etc.) should be stopped for 2 weeks or more; 9. They signed the consent form voluntarily and agreed to participate in the research.

Exclusion criteria

for Chronic Stable Angina group 1. patients who are diagnosed with acute coronary syndrome (including acute myocardial infarction or unstable angina pectoris) occurred within 2 months before enrollment, or had undergone revascularization within 3 months before enrollment, or planned to undergo revascularization during the study period; 2. Patients who are unable to complete Treadmill Exercise Test for various reasons, including absolute and relative contraindications; 3. Severe primary diseases such as respiratory, blood system or malignant tumor, or known renal insufficiency (serum creatinine (CR) \> 221 umol /L in male, or 177 umol / L in female); 4. Patients with epilepsy who had bleeding tendency, history of cerebral hemorrhage, or needed anticonvulsant therapy; 5. Patients with active liver disease, or accompanied with unexplained continuous increase of serum transaminase, or the detection value of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) is more than twice the upper limit of normal reference value; 6. Pregnancy or lactation; 7. patients can't stopped taking long-acting nitrates during the clinical trial; 8. undergoing other clinical trials; 9. There was a history of alcoholism or drug dependence in the past two years; 10. Other situations that the research physician thinks are not suitable to participate in this trial include but are not limited to: the subjects cannot follow the research protocol, which will bring potential safety hazards to the subjects, etc. Eligibility Criteria for Vascular Dementia group Inclusion criteria for Vascular Dementia group 1. The age of the subjects was 35-85 years old; 2. It was in accordance with the diagnostic standard of Western medicine for vascular dementia; 3. It is in accordance with the diagnostic standard of TCM phlegm and blood stasis syndrome of vascular dementia; 4. They signed informed consent and volunteered to participate in the study; 5. The patients are expected to follow up within half a year.

Design outcomes

Primary

MeasureTime frameDescription
Primary endpoint 1 for Chronic Stable Angina Group: the time to ST depression at the end of week 8 compared with baseline on submaximal exercise Modified Bruce Protocol8 weeksIt is suitable for Chronic Stable Angina group. The time to ST depression at the end of week 8 compared with baseline on submaximal exercise Modified Bruce Protocol
Primary endpoint 2 for Chronic Stable Angina group: the score on Syndrome Questionnaire of Intermingled Phlegm and Blood Stasis with Chronic Stable Angina at the end of week 8 compared with baseline8 weeksIt is suitable for Chronic Stable Angina group. Syndrome Questionnaire of Intermingled Phlegm and Blood Stasis with Chronic Stable Angina is a questionnarie to evaluate the severity of Syndrome of Intermingled Phlegm and Blood Stasis with Chronic Stable Angina. The minimum score is 0 and the maximum score is 41. The higher the score is, the worse the outcomes is.
Primary endpoint 1 for Vascular Dementia group: the score of Mini-mental State Examination at the end of month 6 compared with baseline6 monthIt is suitable for Vascular Dementia group. Mini Mental State Examination gives the 'mini-mental state' examination of cognitive function. This is a 5-minute bedside test that is useful as a screen and in assessing the degree of cognitive dysfunction in patients with diffuse brain disorders. The minimum score is 0 and the maximum score is 30. The higher the score is, the better the outcomes is.
Primary endpoint 2 for Vascular Dementia group: the score on Syndrome Questionnaire of Intermingled Phlegm and Blood Stasis with Vascular Dementia at the end of month 6 compared with baseline6 monthIt is suitable for Vascular Dementia group Syndrome Questionnaire of Intermingled Phlegm and Blood Stasis with Vascular Dementia is a questionnarie to evaluate the severity of Syndrome of Intermingled Phlegm and Blood Stasis with Vascular Dementia. The minimum score is 0 and the maximum score is 46. The higher the score is, the worse the outcomes is.
Primary endpoint 1 for Idiopathic Membranous Nephropathy group: level of the 24 hour urine protein quantification at the end of month 6 compared with baseline6 monthsIt is suitable for Idiopathic Membranous Nephropathy group. level of the 24 hour urine protein quantification at the end of month 6 compared with baseline. To evaluate the drug efficiency by comparing date changes of 24 hour urine protein quantification before and 6 months after treatment by Danzhu Fuyuan Granule . The unit of 24 hour urine protein quantification values is described as g/24h
Primary endpoint 2 for Idiopathic Membranous Nephropathy group: the score on Syndrome Questionnaire of Intermingled Phlegm and Blood Stasis with Idiopathic Membranous Nephropathy at the end of month 6 compared with baseline6 monthsIt is suitable for Idiopathic Membranous Nephropathy group. Syndrome Questionnaire of Intermingled Phlegm and Blood Stasis withIdiopathic Membranous Nephropathy is a questionnarie to evaluate the severity of Syndrome of Intermingled Phlegm and Blood Stasis with Idiopathic Membranous Nephropathy. The minimum score is 0 and the maximum score is 42. The higher the score is, the worse the outcomes is.

Secondary

MeasureTime frameDescription
Brain pulse index mearsured by Transcranial Doppler6 monthsIt is suitable for Vascular Dementia group
Arterial systolic blood flow velocity mearsured by Transcranial Doppler6 monthsIt is suitable for Vascular Dementia group
Mean flow velocity mearsured by Transcranial Doppler6 monthsIt is suitable for Vascular Dementia group
Duke treadmill score (DTS) at the end of week 8 compared with baseline on submaximal exercise Modified Bruce Protocol8 weeksIt is suitable for Chronic Stable Angina group. The Duke Treadmill Score was introduced in 1991 as a set of treadmill exercise findings that predict individual risk for death on the basis of a weighted combination of exercise duration, ST-segment depression, and the presence and nature of angina during testing. The score is calculated by subtracting 5 times the ST depression (in millimeters) and 4 times the angina score (no angina = 0, nonlimiting angina = 1, and test-limiting angina = 2) from minutes of exercise duration on the Modified Bruce protocol
Level of blood urea nitrogen6 monthsIt is sutitable for Idiopathic Membranous Nephropathy group.
Glomerular filtration rate6 monthsIt is for idiopathic membranous nephropathy group. It was calculated according to ckD-EPI 2009 formula
Level of serum creatinine6 monthsIt is suitable for Idiopathic Membranous Nephropathy group.
the score on Seattle Angina Questionnaire8 weeksIt is suitable for Chronic Stable Angina group. The Seattle Angina Questionnaire (SAQ) is a self-administered, disease-specific measure for patients with Cornary Artery Disease that is valid, reproducible, and sensitive to clinical change. The SAQ quantifies patients' physical limitations caused by angina, the frequency of and recent changes in their symptoms, their satisfaction with treatment, and the degree to which they perceive their disease to affect their quality of life. Each scale is transformed to a score of 0 to 100, where higher scores indicate better function (eg, less physical limitation, less angina, and better quality of life).
Frequency of weekly angina episodes8 weeksIt is suitable for Chronic Stable Angina group
Angina pectoris severity classification according to Canadian Cardiovascular Society (CCS)8 weeksIt is suitable for Chronic Stable Angina group
Stopping or reducing rate of the Nitroglycerin Table8 weeksIt issuitable for Chronic Stable Angina group
Number of subjects with adverse events or severe adverse events8 weeksIt is suitable for Chronic Stable Angina group

Countries

China

Contacts

Primary ContactXu Weiming, Doctor
15652608470@126.com86-1064089029

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026